Close X
Get more out of WDDTY.com
by joining the site for free
Free 17-point plan to great health
Twice weekly e-news bulletins
Access to our News, Forums and Blogs
Sign up for free and claim your
17-point plan to great health
Free 17-point plan to great health

Twice weekly e-news bulletins

Access to our News, Forums and Blogs
OR

If you want to read our in-depth research articles or
have our amazing magazine delivered to your home
each month, then you have to pay.


Click here if you're interested
Helping you make better health choices

In shops now or delivered to your home from only £3.50 an issue!

Subscribe!

No Cure, No Charge: How to make a drug company bankrupt
About the author: 

Now here's an interesting idea that is being tested in the UK

Now here's an interesting idea that is being tested in the UK. A drug company has agreed to charge the country's National Health Service for its multiple myeloma drug Velcade (bortezomib) only if it cures the patient.

It will refund the full cost of the drug to every patient who doesn't respond to the drug, provided it is prescribed according to the company's specifications. Doctors should use the drug only if other drugs have failed, and the patient is not suitable for bone marrow transplantation.

A correspondent for the British Medical Journal commented: "The announcement was a sobering reminder that most medicines do not work in all patients."

We think it's a great scheme. If it was adopted globally, drug companies would be bankrupt by Christmas.

(Source: British Medical Journal, 2007; 335: 122-3).

Click here to receive health news by email.


You may also be interested in...

Latest Tweet

About

Since 1989, WDDTY has provided thousands of resources on how to beat asthma, arthritis, depression and many other chronic conditions.

Start by looking in our fully searchable database, active and friendly community forums and the latest health news.

Positive SSL Wildcard

Facebook Twitter

Most Popular Health Website of the Year 2014

© 2010 - 2017 WDDTY Publishing Ltd.
All Rights Reserved